ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0483

Frequent Use of Prescription Oral NSAIDs Among People with Knee or Hip Osteoarthritis Despite Contraindications to or Precautions with NSAIDs

Tuhina Neogi1, Andrea Dell'isola2, Martin Englund2 and Aleksandra Turkiewicz2, 1Boston University School of Medicine, Boston, MA, 2Lund University, Lund, Sweden

Meeting: ACR Convergence 2021

Keywords: Comorbidity, Epidemiology, Nonsteroidal antiinflammatory drugs (NSAIDs), Osteoarthritis

  • Tweet
  • Email
  • Print
Session Information

Date: Saturday, November 6, 2021

Title: Abstracts: Osteoarthritis – Clinical (0478–0483)

Session Type: Abstract Session

Session Time: 3:15PM-3:30PM

Background/Purpose: Oral NSAIDs are recommended for OA management. However, many patients with OA have contraindications to NSAIDs or have comorbidities that warrant precaution. Because few other oral therapies are available, such patients may still receive NSAIDs or may instead receive opioids, which are not recommended and have numerous concerning adverse effects. They may also receive physical therapy (PT), an effective option, as a safe alternative. We evaluated the patterns of NSAID, opioid, and PT use among persons with newly diagnosed knee or hip OA with and without NSAID contraindications or precautions using population-based Swedish register data.

Methods: We used register data on healthcare use and dispensed drugs, and population register to identify adults aged ≥35 as of Jan 1, 2010 residing in Skåne region in Sweden, between 1998-2009 and without a knee or hip OA diagnosis during this time. Among this cohort, we identified people with incident knee or hip OA using ICD-10 codes between 2010- 2015. We identified contraindications to or precautions for oral NSAIDs based on ICD-10 codes prior to or at the time of OA diagnosis. Contraindications included gastrointestinal bleed/ ulcer, chronic kidney disease (CKD) stage ≥3 (dialysis, transplant), acute renal failure. Precautions included coronary artery disease, heart failure, gastroesophageal reflux disease, inflammatory bowel disease, CKD stage 1 or 2, other kidney diseases. During the first year after a new OA diagnosis among those with vs. without contraindications or precautions, we evaluated the prevalence and relative risk of: 1) regular oral NSAID use (see Figure 1 for definition); 2) regular opioid use (see Fig 1); 3) physical therapy visit descriptively and in confounder-adjusted logistic regression models with standardization to compute risk ratios.

Results: We included 30,320 persons (21,682 knee OA; 9124 hip OA; 486 were diagnosed with both on the same date; mean age 67, ~41% male, Table 1). Overall, 9.1% had contraindications to NSAIDs, and 21.7% had at least one precaution. There was lower prevalence of regular NSAID use among those with vs. without contraindication to NSAIDs (22% vs. 30%), but higher prevalence of regular opioid use (21% vs. 15%) (Figure 1a); a similar pattern was seen for those with vs. without precautions for NSAIDs (NSAID use: 23% vs. 32%; (opioid use: 18% vs. 14%) (Figure 1b). The lowest prevalence of regular NSAID use was among those with CKD stage ≥3 (10%); they also had highest prevalence of regular opioid use (25%). Prevalence of PT was slightly lower among those with contraindications (51%) or precautions (50%) than those without (55% and 57%, respectively). In adjusted analyses, those with contraindications or precautions were at 1.2 to 1.5 times higher risk of regular opioid prescriptions than those without, while use of PT was not increased for any group (Figure 2).

Conclusion: People with knee or hip OA who have contraindications to or precautions for NSAIDs had higher risk of regular opioid use, but not PT, within the first year of their OA diagnosis. These data highlight the negative impact of having a paucity of treatment options for people with OA who are unable to safely use NSAIDs, and lack of sufficient use of PT for these at-risk patients.

Figure 1. Crude prevalence of NSAIDs, opioid and physical therapy (PT) in persons with newly diagnosed knee or hip OA during the first year after diagnosis, by presence of contraindications or precautions for NSAIDs use. Regular use of NSAIDs or opioids were defined as ≥30 total daily doses prescribed within 90 days from first prescription to ensure regular use for something other than an acute problem.

Figure 2. Adjusted risk ratios of NSAIDs, opioid and physical therapy (PT) use in persons with newly diagnosed knee or hip OA during the first year after diagnosis, comparing those with and without contraindications and precautions of NSAIDs use. The logistic regression model was adjusted for age-group, sex, marital status, if born outside Sweden, income group, education level, year of OA diagnosis, healthcare use (operationalized in 5 variables, if inpatient visit, if specialist contact with psychiatry, categorized number of specialist visits in somatic care, primary care and with other healthcare professionals [not physicians]). Risk ratios were derived using method of standardization.


Disclosures: T. Neogi, Pfizer/Lilly, 2, Regeneron, 2, Novartis, 2; A. Dell'isola, None; M. Englund, None; A. Turkiewicz, None.

To cite this abstract in AMA style:

Neogi T, Dell'isola A, Englund M, Turkiewicz A. Frequent Use of Prescription Oral NSAIDs Among People with Knee or Hip Osteoarthritis Despite Contraindications to or Precautions with NSAIDs [abstract]. Arthritis Rheumatol. 2021; 73 (suppl 9). https://acrabstracts.org/abstract/frequent-use-of-prescription-oral-nsaids-among-people-with-knee-or-hip-osteoarthritis-despite-contraindications-to-or-precautions-with-nsaids/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2021

ACR Meeting Abstracts - https://acrabstracts.org/abstract/frequent-use-of-prescription-oral-nsaids-among-people-with-knee-or-hip-osteoarthritis-despite-contraindications-to-or-precautions-with-nsaids/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology